Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.

ABSTRACT:

Objective

Compare the efficacy and safety of the 2-drug antiretroviral therapy regimen dolutegravir + lamivudine (DTG + 3TC) with traditional 3-drug regimens in treatment-naive patients with HIV-1.

Design

Data from double-blind, randomized controlled trials of at least 48 weeks' duration in treatment-naive patients with HIV-1 identified by systematic review were evaluated using a Bayesian network meta-analysis methodology.

Methods

The primary outcome was virologic suppression at Week 48 for 3-drug regimens versus DTG + 3TC (also analyzed in patient subgroup with baseline viral load >100 000 RNA copies/ml). Secondary outcomes included CD4 cell count change from baseline and safety (adverse events, serious adverse events, and drug-related adverse events) at Week 48.

SUBMITTER: Radford M 

PROVIDER: S-EPMC6686958 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature